Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.47 |
| ▸ | KDR | P35968 | 9/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282736 | 0.90 | SRC (0.57) | SRCKDREGFR | |
| SCHEMBL3277252 | 0.85 | SRC (0.62) | SRCKDREGFR | |
| SCHEMBL3282155 | 0.82 | SRC (0.55) | SRCKDRNPC1NCOA1NCOA3 | |
| SCHEMBL3280279 | 0.77 | SRC (0.59) | SRCKDREGFR | |
| SCHEMBL3276553 | 0.76 | SRC (0.69) | SRCKDREGFREPHA2EPHB4 | |
| SCHEMBL3279077 | 0.75 | SRC (0.77) | SRCKDREGFR | |
| SCHEMBL3277072 | 0.74 | SRC (0.57) | SRCKDRNPC1NCOA1NCOA3 | |
| SCHEMBL3275923 | 0.73 | SRC (0.70) | SRCKDREGFREPHA2EPHB4 | |
| SCHEMBL3194243 | 0.73 | SRC (0.81) | SRCKDREGFR | |
| Hydrochloric Acid SCHEMBL3275336 | 0.73 | SRC (0.57) | SRCKDREGFREPHA2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696214-B2 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | SRC 1986/4885KDR 2002/4885NPC1 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.